In this clinical trial, we investigate how the study compound is processed and eliminated by the body when it is taken alone or in combination with an approved medicine which is already available on the market (atazanavir). Atazanavir is being used for the treatment of human immunodeficiency virus (HIV). In addition, it is investigated how well the study compound is tolerated when it is used by healthy participants.  Furthermore, it will also be investigated how well the study compound is absorbed by the body when given by mouth compared to an intravenous administration (administration directly into a blood vessel).

• You are a healthy male or female.
• You are at least 18 and at most 55 years old.
• Your weight is at least 60 kg and your Body Mass Index (BMI) is at least 18.0 and at most 29.9 kg/m2. 
• Both non-smokers and light smokers or occasional smokers are allowed to participate (maximum of 5 cigarettes per day) in this clinical trial. During your stay in our research facility, you are not allowed to smoke.

Note:

• You cannot participate in the trial if you have participated in another clinical trial in the 3 months prior to the first study compound administration in this clinical trial (counting from the follow-up visit).
• To determine if you are suitable to participate in this trial, you will undergo a medical screening. Depending on availability, this can be performed in Groningen or in Utrecht.

• As a female you can only participate if you are not pregnant, not breast feeding and meet one of the following conditions:
  • You have passed the menopause (no periods for at least 12 months);
  • You have been sterilized.
• As a male you can only participate if you meet one of the following conditions:
  • You are using a condom in combination with an additional highly effective contraceptive  method used by your female partner;
  • You have been sterilized or your female partner is sterilized or has passed the menopause (no periods for at least 12 months);
  • You are not sexually active according to your lifestyle;
  • You are only sexually active with a partner of the same sex.

The trial consists of 1 in-house period during which you will stay in the research facility in Groningen (location van Swietenlaan 6) for 17 days (16 nights). The follow-up visit will take place 8 to 12 days after the last administration of the study compound.

Note: You must be available for all dates to be able to participate in this clinical trial.